Drug Search Results

Besilesomab

Alternative Names: besilesomab
Latest Update: 2025-01-30
Latest Update Note: News Article

Product Description

Mechanisms of Action: IgG Imaging Agent,IgG Radioactive Agent

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: Orphan Drug - Bone Marrow Transplantation *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Great Ormond Street Hospital for Children NHS Foundation Trust
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Besilesomab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Skin Ulcer|Osteomyelitis|Diabetic Foot

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
2006-000514-21	P3	Completed	Osteomyelitis\|Skin Ulcer\|Diabetic Foot	2008-01-05

Recent News Events

Date	Type	Title
02/13/2025	News Article	Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)
02/12/2025	News Article	Illuccix® Approved in the United Kingdom
01/30/2025	News Article	Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
01/27/2025	News Article	Telix Completes Acquisition of RLS (USA) Inc.
08/17/2023	PubMed	Semi-quantitative analysis with (99m)Tc-Besilesomab in musculoskeletal system infections.
01/01/2021	PubMed	Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases.
11/01/2020	PubMed	Combined Techniques of Non-invasive (99m)Tc-Besilesomab/(99m)Tc-Sulfur Colloid with Hybrid SPECT/CT Imaging in Characterising Cellulitis from Symptomatic Perimegaprosthetic Infection: A Case Report.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions